A PYMNTS Company

US: Teva/Generic Drugmakers aim to settle antitrust case

By  |  November 25, 2019

A number of generic drugmakers are aiming to resolve a criminal antitrust probe launched by the US Justice Department (DOJ), a report from Bloomberg stated.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    One potential resolution would be a deferred prosecution agreement, in which the companies would admit to some of the agency’s allegations, pay fines, and cooperate with the inquiry but would not be indicted, people familiar with the matter told Bloomberg.

    The talks aren’t certain to lead to agreements with any or all of the companies, the news service reported. Teva Pharmaceutical  of Israel and Sun Pharmaceutical of India have been in talks with the justice agency, Bloomberg reported.

    Teva told Bloomberg that it was cooperating with the DOJ and would consider resolving the matter if an accord “makes sense for the company,” its holders, and the patients who rely on the company’s products.

    Full Content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.